Merck & Co., Inc. - MRK Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $106.00
  • Forecasted Upside: -4.38 %
  • Number of Analysts: 17
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 12 Buy Ratings
  • 1 Strong Buy Ratings
$110.85
▲ +0.76 (0.69%)

This chart shows the closing price for MRK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Merck & Co., Inc. Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRK

Analyst Price Target is $106.00
▼ -4.38% Downside Potential
This price target is based on 17 analysts offering 12 month price targets for Merck & Co., Inc. in the last 3 months. The average price target is $106.00, with a high forecast of $122.00 and a low forecast of $93.00. The average price target represents a -4.38% upside from the last price of $110.85.

This chart shows the closing price for MRK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 17 investment analysts is to buy stock in Merck & Co., Inc.. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/15/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/13/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/12/2021
  • 1 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/12/2022
  • 1 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/10/2022
  • 1 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 0 sell ratings
9/8/2022
  • 1 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 0 sell ratings
11/7/2022
  • 1 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/7/2022

Latest Recommendations

  • 1 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/17/2022Credit Suisse GroupInitiated CoverageOutperform$120.00Low
11/15/2022CitigroupBoost Target$105.00Low
11/1/2022GuggenheimBoost TargetBuy$104.00 ➝ $111.00Low
10/28/2022BarclaysBoost TargetOverweight$105.00 ➝ $110.00Low
10/28/2022Wells Fargo & CompanyBoost TargetOverweight$105.00 ➝ $110.00Low
10/28/2022Truist FinancialBoost TargetBuy$103.00 ➝ $106.00Low
10/28/2022SVB LeerinkBoost TargetOutperform$110.00 ➝ $112.00Low
10/28/2022Morgan StanleyBoost TargetEqual Weight$91.00 ➝ $100.00Low
10/28/2022Cantor FitzgeraldBoost Target$107.00 ➝ $120.00Low
10/28/2022Atlantic SecuritiesBoost TargetOverweight$116.00 ➝ $122.00Low
10/12/2022Morgan StanleyLower TargetEqual Weight$92.00 ➝ $91.00Low
10/12/2022BarclaysBoost Target$101.00 ➝ $105.00Low
10/11/2022Atlantic SecuritiesBoost TargetOverweight$110.00 ➝ $116.00Low
10/11/2022Truist FinancialBoost Target$95.00 ➝ $103.00Low
10/10/2022GuggenheimUpgradeNeutral ➝ Buy$104.00Low
9/30/2022SVB LeerinkBoost TargetOutperform$109.00 ➝ $110.00Low
9/14/2022Berenberg BankUpgradeHold ➝ Buy$95.00 ➝ $100.00Low
9/12/2022SVB LeerinkBoost TargetOutperform$105.00 ➝ $109.00Low
8/25/2022Erste Group BankUpgradeHold ➝ BuyLow
7/29/2022Morgan StanleyBoost TargetEqual Weight$88.00 ➝ $92.00Low
7/18/2022UBS GroupBoost TargetNeutral$76.00 ➝ $98.00Low
7/13/2022Atlantic SecuritiesBoost TargetOverweight$105.00 ➝ $110.00N/A
7/8/2022Morgan StanleyBoost TargetEqual Weight$87.00 ➝ $88.00N/A
7/6/2022Daiwa Capital MarketsUpgradeNeutral ➝ Buy$89.00 ➝ $102.00N/A
6/27/2022CowenBoost TargetMarket Perform$95.00 ➝ $102.00Low
6/27/2022CowenBoost TargetMarket Perform$95.00 ➝ $102.00Low
6/24/2022MizuhoInitiated CoverageBuy$100.00Low
6/6/2022SVB LeerinkReiterated RatingOutperform$102.00Low
4/21/2022SVB LeerinkLower TargetOutperform$100.00 ➝ $97.00Low
4/12/2022BarclaysBoost TargetOverweight$94.00 ➝ $97.00Medium
4/6/2022Morgan StanleyLower TargetEqual Weight$82.00 ➝ $80.00Low
4/6/2022SVB LeerinkLower TargetOutperform$101.00 ➝ $100.00Medium
4/1/2022MizuhoInitiated CoverageBuy$100.00Medium
2/4/2022SVB LeerinkLower TargetOutperform$102.00 ➝ $101.00Medium
1/28/2022JPMorgan Chase & Co.Lower TargetOverweight$100.00 ➝ $95.00Low
12/23/2021MizuhoInitiated CoverageBuy$100.00Low
12/17/2021The Goldman Sachs GroupInitiated CoverageConviction-Buy$93.00High
12/16/2021Daiwa Capital MarketsInitiated CoverageNeutral$70.00Medium
12/13/2021MizuhoReiterated RatingBuyHigh
12/13/2021UBS GroupDowngradeBuy ➝ Neutral$98.00 ➝ $76.00High
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$90.00Low
12/7/2021GuggenheimDowngradeBuy ➝ Neutral$98.00Low
11/30/2021SVB LeerinkReiterated RatingBuyLow
11/29/2021Morgan StanleyLower TargetSell ➝ Equal Weight$88.00 ➝ $82.00High
11/29/2021CitigroupDowngradeBuy ➝ Neutral$105.00 ➝ $85.00High
11/24/2021Truist FinancialBoost TargetBuy$92.00 ➝ $95.00Low
11/18/2021BMO Capital MarketsInitiated CoverageMarket Perform$91.00High
11/1/2021BarclaysBoost TargetOverweight$92.00 ➝ $94.00Low
11/1/2021ArgusUpgradeHold ➝ Buy$110.00Low
10/29/2021Morgan StanleyBoost TargetEqual Weight$88.00 ➝ $90.00Low
10/28/2021MizuhoInitiated CoverageBuy$99.00High
10/22/2021SVB LeerinkBoost TargetOutperform$104.00 ➝ $105.00Low
10/12/2021Morgan StanleyBoost TargetEqual Weight$85.00 ➝ $88.00Medium
10/10/2021Berenberg BankReiterated RatingHold$86.00 ➝ $92.00Low
10/8/2021BarclaysBoost TargetOverweight$87.00 ➝ $92.00Low
10/4/2021SVB LeerinkBoost TargetOutperform$101.00 ➝ $104.00Medium
10/1/2021MizuhoInitiated CoverageBuy$100.00High
9/7/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$90.00 ➝ $85.00High
7/30/2021SVB LeerinkBoost TargetOutperform$99.00 ➝ $101.00Low
7/27/2021Truist FinancialInitiated CoverageBuy$76.79Low
6/9/2021JPMorgan Chase & Co.Lower TargetOverweight$105.00 ➝ $100.00Medium
6/7/2021Truist FinancialLower TargetBuy$96.00 ➝ $93.00High
6/3/2021SVB LeerinkLower TargetOutperform$102.00 ➝ $99.00Medium
5/20/2021ArgusReiterated RatingBuy ➝ HoldMedium
4/30/2021SVB LeerinkLower TargetOutperform$103.00 ➝ $102.00Low
2/5/2021Cantor FitzgeraldReiterated RatingOverweightMedium
12/6/2020MizuhoReiterated RatingBuy$100.00Low
11/10/2020Sanford C. BernsteinReiterated RatingOutperform$95.00Low
10/29/2020SVB LeerinkBoost TargetOutperform$100.00 ➝ $103.00Low
10/23/2020Truist FinancialInitiated CoverageBuy$96.00Low
10/16/2020JPMorgan Chase & Co.Boost TargetOverweight$98.00 ➝ $105.00Low
9/29/2020Berenberg BankInitiated CoverageHold$88.00Medium
9/22/2020MizuhoReiterated RatingBuyLow
8/25/2020SVB LeerinkBoost TargetOutperform$95.00 ➝ $100.00Low
8/4/2020Royal Bank of CanadaReiterated RatingHoldMedium
8/3/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$91.00 ➝ $105.00High
7/31/2020MizuhoReiterated RatingBuy$100.00Low
6/23/2020MizuhoReiterated RatingBuy$100.00Medium
6/23/2020Morgan StanleyReiterated RatingBuy$89.00Medium
6/12/2020Wolfe ResearchDowngradeOutperform ➝ Peer PerformMedium
5/4/2020Credit Suisse GroupReiterated RatingBuy$95.00Low
4/29/2020GuggenheimLower TargetBuy$101.00 ➝ $93.00Low
4/29/2020BarclaysLower TargetOverweight$93.00 ➝ $90.00Low
4/29/2020SVB LeerinkLower TargetOutperform$98.00 ➝ $95.00Low
4/13/2020UBS GroupLower TargetBuy$96.00 ➝ $92.00Low
4/2/2020Morgan StanleyLower TargetOverweight$97.00 ➝ $89.00Medium
4/1/2020Royal Bank of CanadaLower TargetSector Perform$92.00 ➝ $89.00Low
3/24/2020ArgusLower TargetBuy$105.00 ➝ $95.00Low
2/27/2020BarclaysInitiated CoverageOverweight$93.00Medium
2/6/2020Royal Bank of CanadaReiterated RatingSector Perform$92.00Low
2/6/2020UBS GroupLower TargetBuy$99.00 ➝ $96.00Low
2/5/2020MizuhoReiterated RatingBuyHigh
1/23/2020UBS GroupBoost TargetBuy$94.00 ➝ $99.00Low
1/8/2020Cantor FitzgeraldReiterated RatingBuy$95.00Medium
1/6/2020MizuhoReiterated RatingBuy$100.00High
1/6/2020Royal Bank of CanadaInitiated CoverageSector Perform$99.00High
11/13/2019Morgan StanleyBoost TargetOverweight$90.00 ➝ $95.00Low
10/30/2019MizuhoBoost TargetBuy$97.00 ➝ $100.00Medium
10/18/2019MizuhoReiterated RatingBuy$97.00Low
10/16/2019Bank of AmericaInitiated CoverageNeutral$90.00Low
10/10/2019JPMorgan Chase & Co.Set TargetBuy$96.00Low
9/8/2019MizuhoReiterated RatingBuy$97.00High
9/3/2019Societe GeneraleSet TargetBuy$105.00Low
8/16/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$103.00Low
8/7/2019Credit Suisse GroupReiterated RatingBuy$95.00Low
8/7/2019ArgusBoost TargetHold ➝ Buy$105.00Low
8/5/2019MizuhoReiterated RatingBuy$97.00Low
7/11/2019Credit Suisse GroupInitiated CoverageBuy$95.00Low
7/11/2019Bank of AmericaSet TargetBuy$97.00High
7/2/2019MizuhoInitiated CoverageBuy ➝ Buy$97.00Low
6/21/2019Bank of AmericaBoost TargetBuy$91.00 ➝ $96.00Medium
6/21/2019Morgan StanleyBoost TargetOverweight$84.00 ➝ $90.00Low
6/21/2019CitigroupBoost TargetBuy$84.00 ➝ $95.00Low
6/14/2019JPMorgan Chase & Co.Boost TargetOverweight$90.00 ➝ $93.00Low
5/28/2019The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$85.00Medium
5/13/2019Atlantic SecuritiesUpgradeNeutral ➝ OverweightLow
5/2/2019UBS GroupBoost TargetBuy ➝ Buy$87.00 ➝ $88.00Medium
5/1/2019Bank of AmericaBoost TargetBuy ➝ Buy$90.00 ➝ $91.00Low
5/1/2019BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$83.00 ➝ $84.00Low
3/29/2019Cantor FitzgeraldReiterated RatingBuy$95.00Low
3/4/2019Cantor FitzgeraldReiterated RatingBuy$95.00Low
2/22/2019Cantor FitzgeraldInitiated CoverageOverweight$95.00Low
2/20/2019ArgusBoost TargetHold ➝ Buy$95.00Low
2/19/2019BMO Capital MarketsReiterated RatingHoldLow
1/23/2019BMO Capital MarketsDowngradeOutperform ➝ Market Perform$80.00Low
12/20/2018CitigroupSet TargetHold$65.00Low
12/20/2018Morgan StanleySet TargetBuy$81.00Medium
12/13/2018Credit Suisse GroupSet TargetBuy$86.00Low
10/31/2018CitigroupBoost TargetBuy ➝ Buy$79.00 ➝ $84.00Low
10/29/2018SunTrust BanksBoost TargetBuy ➝ Buy$77.00 ➝ $80.00Low
10/23/2018Wolfe ResearchInitiated CoverageOutperformLow
10/22/2018BMO Capital MarketsBoost TargetOutperform ➝ Outperform$70.00 ➝ $82.00Low
10/16/2018CitigroupSet TargetBuy ➝ Buy$70.00 ➝ $79.00Medium
10/12/2018BarclaysBoost TargetOverweight$75.00 ➝ $78.00Low
10/11/2018Credit Suisse GroupBoost TargetOutperform$71.00 ➝ $81.00High
10/8/2018GuggenheimInitiated CoverageBuy ➝ BuyLow
9/7/2018BarclaysBoost TargetOverweight ➝ Overweight$70.00 ➝ $75.00Low
8/23/2018Morgan StanleySet TargetOverweight ➝ Buy$68.00 ➝ $74.00Low
8/16/2018SunTrust BanksReiterated RatingBuy$77.00Low
7/30/2018Bank of AmericaBoost TargetBuy ➝ Buy$70.00 ➝ $74.00Medium
7/22/2018BMO Capital MarketsReiterated RatingBuy$70.00Low
7/15/2018Jefferies Financial GroupReiterated RatingHold$59.00Low
4/26/2018BMO Capital MarketsBoost TargetOutperform ➝ Outperform$65.00 ➝ $70.00Low
4/25/2018BMO Capital MarketsReiterated RatingBuyLow
4/25/2018Deutsche Bank AktiengesellschaftReiterated RatingHoldLow
4/23/2018The Goldman Sachs GroupUpgradeNeutral ➝ Buy$60.15 ➝ $58.83Low
4/20/2018CowenReiterated RatingHold$67.00Low
4/17/2018Bank of AmericaBoost TargetBuy ➝ Buy$68.00 ➝ $70.00Low
4/17/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$59.80 ➝ $63.00Low
4/16/2018BMO Capital MarketsReiterated RatingBuy$65.00High
4/13/2018Jefferies Financial GroupSet TargetHold$56.00Low
4/6/2018BMO Capital MarketsSet TargetBuy$65.00High
4/5/2018BarclaysUpgradeEqual Weight ➝ Overweight$62.00 ➝ $64.00Low
3/23/2018Jefferies Financial GroupSet TargetHold$55.00Medium
3/12/2018SVB LeerinkUpgradeMarket Perform ➝ OutperformLow
3/8/2018BMO Capital MarketsSet TargetBuy$65.00Low
2/26/2018Jefferies Financial GroupSet TargetHold$56.00Low
2/21/2018BMO Capital MarketsSet TargetBuy$65.00Low
2/14/2018SVB LeerinkLower TargetMkt Perform ➝ Market Perform$67.00 ➝ $66.00Low
2/14/2018Credit Suisse GroupLower TargetOutperform ➝ Outperform$66.00 ➝ $65.00Low
2/13/2018BMO Capital MarketsSet TargetOutperform ➝ Outperform$70.00 ➝ $65.00Low
2/13/2018DZ BankUpgradeHold ➝ BuyLow
2/7/2018Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$60.00 ➝ $63.00Low
2/6/2018SVB LeerinkLower TargetMarket Perform ➝ Market Perform$69.00 ➝ $67.00High
2/5/2018Credit Suisse GroupLower TargetOutperform ➝ Outperform$67.00 ➝ $66.00High
1/17/2018BMO Capital MarketsBoost TargetOutperform$68.00 ➝ $72.00Low
1/16/2018Jefferies Financial GroupReiterated RatingHold$55.00Low
1/16/2018SunTrust BanksUpgradeHold ➝ Buy$54.00 ➝ $72.00High
1/16/2018BMO Capital MarketsSet TargetBuy$68.00High
12/13/2017BMO Capital MarketsSet TargetBuy$68.00Low
(Data available from 12/8/2017 forward)

News Sentiment Rating

0.64 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 12 very positive mentions
  • 43 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
5/12/2022
  • 9 very positive mentions
  • 28 positive mentions
  • 4 negative mentions
  • 4 very negative mentions
6/11/2022
  • 23 very positive mentions
  • 39 positive mentions
  • 3 negative mentions
  • 9 very negative mentions
7/11/2022
  • 19 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
8/10/2022
  • 16 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 5 very negative mentions
9/9/2022
  • 20 very positive mentions
  • 21 positive mentions
  • 8 negative mentions
  • 4 very negative mentions
10/9/2022
  • 34 very positive mentions
  • 35 positive mentions
  • 3 negative mentions
  • 7 very negative mentions
11/8/2022
  • 22 very positive mentions
  • 37 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
12/8/2022

Current Sentiment

  • 22 very positive mentions
  • 37 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Merck & Co., Inc. logo
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Read More

Today's Range

Now: $110.85
Low: $110.12
High: $111.02

50 Day Range

MA: $99.02
Low: $86.12
High: $110.12

52 Week Range

Now: $110.85
Low: $71.97
High: $111.02

Volume

7,353,695 shs

Average Volume

10,663,835 shs

Market Capitalization

$281.05 billion

P/E Ratio

18.44

Dividend Yield

2.51%

Beta

0.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Merck & Co., Inc.?

The following Wall Street research analysts have issued research reports on Merck & Co., Inc. in the last twelve months: Atlantic Securities, Barclays PLC, Berenberg Bank, Cantor Fitzgerald, Citigroup Inc., Cowen Inc, Cowen Inc., Credit Suisse Group AG, Daiwa Capital Markets, Erste Group Bank AG, Guggenheim, JPMorgan Chase & Co., Mizuho, Morgan Stanley, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist Financial Co., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for MRK.

What is the current price target for Merck & Co., Inc.?

18 Wall Street analysts have set twelve-month price targets for Merck & Co., Inc. in the last year. Their average twelve-month price target is $106.00, suggesting a possible downside of 4.4%. Atlantic Securities has the highest price target set, predicting MRK will reach $122.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $93.00 for Merck & Co., Inc. in the next year.
View the latest price targets for MRK.

What is the current consensus analyst rating for Merck & Co., Inc.?

Merck & Co., Inc. currently has 4 hold ratings, 12 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MRK will outperform the market and that investors should add to their positions of Merck & Co., Inc..
View the latest ratings for MRK.

What other companies compete with Merck & Co., Inc.?

How do I contact Merck & Co., Inc.'s investor relations team?

Merck & Co., Inc.'s physical mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company's listed phone number is (908) 740-4000 and its investor relations email address is [email protected] The official website for Merck & Co., Inc. is www.merck.com. Learn More about contacing Merck & Co., Inc. investor relations.